Back to Awarded Treatment Trials
Awarded Trial: 01-055
Grant ID
01-055
Illness
Schizophrenia
Primary Drug/Intervention
Risperidone
Primary Dosage
3mg
Secondary Drug Intervention
Clozapine
Secondary Dosage
at least 400mg/day
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Honer
Sample Size
68
Duration of Study Period for Each Subject
8 weeks
Outcome Measurements
PANSS, ESRS, BAS, CGI, Cognitive Battery
Results
There was no statistically significant difference between risperidone and placebo for patients who had a poor response to clozapine alone with regard to symptom ratings. There were no differences between groups with regard to movement disorder side effects.
Publication
Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, Falkai P, Pomarol-Clotet E, McKenna PJ, Stip E, Williams R, MacEwan GW, Wasan K, Procyshyn R; Clozapine and Risperidone Enhancement (CARE) Study Group. Clozapine Alone versus Clozapine and Risperidone with Refractory Schizophrenia. N Engl J Med. 2006 Feb 2;354(5):472-82.
Link
http://www.ncbi.nlm.nih.gov/pubmed/16452559
PI Name
William Honer
Degree
MD
Center
Centre for Complex Disorders, Jack Bell Chair in Schizophrenia
Institution
University of British Columbia
Address
Vancouver General Hospital Research Pavilion, #211 - 828 West 10th Ave
City or Town
Vancouver
State or Province
British Columbia
Zip or Postal Code
V5Z 1L8
Country
Canada
Email Address
honer@interchange.ubc.ca